Friday, October 04, 2013
Cholesterol Drugs Linked To Eye Damage, JAMA Study Confirms Anew
A new study published in JAMA Ophthalmology titled, “Association of Statin Use With Cataracts: A Propensity Score-Matched Analysis,” reveals that the top-grossing, cholesterol-lowering drug class known as statins is significantly increasing the risk of cataracts within exposed populations.
Statin-induced eye damage will be a surprising finding to some, especially to statin drug advocates who have argued that the purported ‘antioxidant’ effects of statins ‘may slow the natural aging process of the lens.’ This latter, strictly theoretical benefit is increasingly being disproved by the biomedical literature. In fact, last year, we reported in an article titled, “Blind To The Truth: The Eye-Damaging Effects of Statins,” on findings published in Optometry and Vision Science, revealing that statin drugs users have a 48% higher risk of pathological eye lens changes commonly associated with cataract formation.
A cataract is a clouding of the lens of the eye which leads to a decrease in vision, and is a leading cause of blindness in the world. The most commonly identified causes are aging, trauma and excessive UV radiation exposure, along with a still poorly understood genetic component. While there is preclinical evidence that the opacity of the lens can be reversed through natural substances such as wheatgrass, the most common conventional approach is to treat the condition with surgery, which does nothing to mitigate or undo the underlying causes.
Researchers at San Antonio Military Medical Center, San Antonio Texas, compared the risks for development of cataracts between statin users and nonusers, using a military health care system database. The study design was described as follows:
Based on medication fills during fiscal year 2005, patients were divided into 2 groups: (1) statin users (received at least a 90-day supply of statin) and (2) nonusers (never received a statin throughout the study). Among 46 249 patients meeting study criteria, we identified 13 626 statin users and 32 623 nonusers.
The main results were reported as follows:
"For our primary analysis, we matched 6972 pairs of statin users and nonusers. The risk for cataract was higher among statin users in comparison with nonusers in the propensity score-matched cohort (odds ratio, 1.09; 95% CI, 1.02-1.17). In secondary analyses, after adjusting for identified confounders, the incidence of cataract was higher in statin users in comparison with nonusers (odds ratio, 1.27; 95% CI, 1.15-1.40). Sensitivity analysis confirmed this relationship."
In other words, the risk for cataract was between 9% and 27% higher in statin users, leading the study authors to conclude: “The risk for cataract is increased among statin users as compared with nonusers. The risk-benefit ratio of statin use, specifically for primary prevention, should be carefully weighed, and further studies are warranted.”
What is important to point out is that the human eye is an extension of the nervous system, which is the second most lipid- and cholesterol-concentrated tissue type next to adipose tissue in the human body. The lenses of mammals, but particularly the human lens, is extremely stable due in part to its cholesterol content. Amazingly, this is why the only reported lipid remaining in a frozen mammoth 40,000 years after its death was from its lens membranes. Therefore, given the crucial role that cholesterol plays as a structural and functional biomolecule within the eye, is it any wonder that cholesterol-inhibiting drugs adversely affect them?
Also, considering that statin drugs bear a wide range of additional health risks, with over 300 known adverse effects associated with their use extensively documented in the biomedical literature [see our Statin Drug database], the reported cardiovascular benefits of this drug class may not be significant enough any longer to justify their use.
To the contrary, the research increasingly indicates that statin drugs are both muscle-damaging (myotoxic) and nerve-damaging (neurotoxic) – a concerning heart-damaging (cardiotoxic) combination, as the heart muscle is a highly nerve-dense muscle.
At the very least, patients need to be adequately informed of their risks in order for the medico-ethical principle of informed consent to even be possible. Failing that, the drug-based default approach in using statin drugs for the primary and secondary prevention of cardiovascular disease violates the most basic ethical and likely legal rights of their patients.
Struggling to conceive? Try eating a hearty breakfast: Extra calories in the morning increase ovulation -- if you've got polycystic ovary syndrome
Women who struggle to get pregnant should try tucking into a hearty breakfast, new research suggests. The study revealed that eating a big meal in the morning, rather than evening, can help women with polycystic ovary syndrome to conceive.
Having the bulk of the day's calorie intake in the morning helps to regulate insulin, testosterone and other hormones that can have an adverse of a women's chances of getting pregnant.
The findings revealed that glucose levels and insulin resistance decreased by eight per cent in those eating their biggest meal in the morning, while the group who ate their biggest meal at dinner time showed no changes.
Another finding showed that among the 'breakfast' group, levels of the male hormone testosterone dropped by nearly half, while in the 'dinner' group the level stayed the same.
In addition, there was a much higher rate of ovulation in woman within the 'breakfast’ group compared to the 'dinner' group, showing that eating a hearty breakfast leads to an increase in the level of fertility among woman with polycystic ovary syndrome.
Polycystic ovary syndrome affects approximately six to 10 per cent of women of reproductive age, disrupting their reproductive abilities.
It creates a resistance to insulin, leading to an increase in male sex hormones (androgens), and can also cause menstrual irregularities, hair loss on the scalp, increased body hair, acne, fertility problems and diabetes.
Experiments were carried out at The Hebrew University of Jerusalem on 60 women over 12 weeks.
The women, aged between 25 and 39, were thin with a body mass index of less than 23 and suffered from polycystic ovary syndrome.
The women were divided into two groups and were each allowed to consume about 1,800 calories a day.
The difference between the groups was the timing of their largest meal - one group consumed their largest meal, approximately 980 calories, at breakfast, while the other ate their biggest meal of the day in the evening.
Researchers wanted to examine whether the timing of calorie intake affected insulin resistance and the increase in androgens among woman suffering from polycystic ovary syndrome.
Study leader Professor Oren Froy said: ‘The research clearly demonstrates that indeed the amount of calories we consume daily is very important, but the timing as to when we consume them is even more important.’
Posted by jonjayray at 12:21 AM